Search

Displaying results 3931 - 3940 of 6198 in total
  1. Drug

    Propantheline

    go.drugbank.com/drugs/DB00782
    Approved

    A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.

  2. Drug

    Palucorcel

    go.drugbank.com/drugs/DB17955
    Investigational

    Palucorcel is an investigational stem cell therapy consisting of human umbilical tissue-derived cells. … Developed by Janssen Biotech, it is being investigated for the treatment of various conditions such as amyotrophic lateral sclerosis (ALS) and macular degeneration.

  3. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    It is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  4. Drug

    D-Proline

    go.drugbank.com/drugs/DB02853
    Experimental

    These amino acids may be of bacterial origin, but there is also evidence that they are endogenously produced through amino acid racemase activity [A19263]. … D-proline is an isomer of the naturally occurring amino acid, L-Proline. D-amino acids have been found in relatively high abundance in human plasma and saliva [A19262].

  5. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    [A263066] An Denosumab biosimilar, Jubbonti, was approved for Health Canada in February 2024.[L52083]. … [A263066] Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women.

  6. Drug

    SYNB1020

    go.drugbank.com/drugs/DB17667
    Investigational

    SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc. … discontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study.

  7. Drug

    Tosatoxumab

    go.drugbank.com/drugs/DB16557
    Investigational

    protecting against destruction of host cells mediated by the toxin. … Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and thereby preserving human immune cells by

  8. Drug

    V1003

    go.drugbank.com/drugs/DB05046
    Experimental

    V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings.

  9. Drug

    Trichloroethylene

    go.drugbank.com/drugs/DB13323
    Approved

    Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the similar 1,1,1-trichloroethane, also known as chlorothene. … It has been sold under a variety of trade names including Trimar and Trilene and used as a volatile anesthetic and as an inhaled obstetrical analgesic.

  10. Drug

    Galactose-uridine-5'-diphosphate

    go.drugbank.com/drugs/DB03501
    Experimental

    A nucleoside diphosphate sugar which can be epimerized into UDPglucose for entry into the mainstream of carbohydrate metabolism.